Real-world data on STRIDE-II treatment targets in a pediatric cohort with inflammatory bowel disease.

In CD, patients with SES‐CD < 3 or absence of ulcerations were paradoxically less likely to have met targets by Week 26, whereas in UC, achieving targets by Week 26 showed a trend toward better endoscopic outcomes (Table 2 ). 4 DISCUSSION Based on updated STRIDE‐II recommendations, we analyzed outcomes of pediatric IBD patients during the first year post‐diagnosis in a real‐world setting, assessing time to clinical, fecal, and serum biomarker remission as well as relapse.

also in 53,322 other papers